Walkner Condon Financial Advisors LLC Raises Stake in AbbVie Inc. $ABBV

Walkner Condon Financial Advisors LLC raised its stake in shares of AbbVie Inc. (NYSE:ABBV) by 14.5% in the second quarter, Holdings Channel reports. The institutional investor owned 2,533 shares of the company’s stock after buying an additional 321 shares during the quarter. Walkner Condon Financial Advisors LLC’s holdings in AbbVie were worth $470,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors have also recently modified their holdings of ABBV. FF Advisors LLC grew its position in shares of AbbVie by 3.6% during the 2nd quarter. FF Advisors LLC now owns 1,539 shares of the company’s stock valued at $286,000 after purchasing an additional 53 shares in the last quarter. Private Management Group Inc. increased its position in shares of AbbVie by 1.9% in the first quarter. Private Management Group Inc. now owns 2,938 shares of the company’s stock worth $616,000 after purchasing an additional 54 shares during the last quarter. LifeSteps Financial Inc. raised its stake in AbbVie by 0.7% in the second quarter. LifeSteps Financial Inc. now owns 7,358 shares of the company’s stock valued at $1,366,000 after purchasing an additional 54 shares in the last quarter. Silicon Valley Capital Partners raised its stake in AbbVie by 10.8% in the first quarter. Silicon Valley Capital Partners now owns 573 shares of the company’s stock valued at $118,000 after purchasing an additional 56 shares in the last quarter. Finally, Seneca House Advisors lifted its position in AbbVie by 2.7% during the second quarter. Seneca House Advisors now owns 2,093 shares of the company’s stock valued at $388,000 after purchasing an additional 56 shares during the last quarter. 70.23% of the stock is currently owned by institutional investors.

Insider Activity

In related news, EVP Azita Saleki-Gerhardt sold 42,370 shares of the business’s stock in a transaction dated Tuesday, August 12th. The shares were sold at an average price of $198.42, for a total transaction of $8,407,055.40. Following the transaction, the executive vice president owned 177,292 shares in the company, valued at $35,178,278.64. The trade was a 19.29% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Company insiders own 0.25% of the company’s stock.

AbbVie Price Performance

ABBV opened at $218.92 on Friday. The company has a debt-to-equity ratio of 44.14, a current ratio of 0.74 and a quick ratio of 0.61. The stock’s 50 day simple moving average is $223.24 and its 200 day simple moving average is $202.30. The firm has a market cap of $386.74 billion, a price-to-earnings ratio of 104.25, a PEG ratio of 1.42 and a beta of 0.50. AbbVie Inc. has a 1 year low of $163.81 and a 1 year high of $244.81.

AbbVie (NYSE:ABBV) last announced its quarterly earnings data on Friday, October 31st. The company reported $1.86 earnings per share for the quarter, beating the consensus estimate of $1.77 by $0.09. AbbVie had a return on equity of 699.66% and a net margin of 6.45%.The firm had revenue of $15.78 billion during the quarter, compared to the consensus estimate of $15.58 billion. During the same quarter in the previous year, the company posted $3.00 earnings per share. The business’s revenue was up 9.1% on a year-over-year basis. AbbVie has set its Q4 2025 guidance at 3.320-3.360 EPS. As a group, analysts predict that AbbVie Inc. will post 12.31 earnings per share for the current year.

AbbVie Increases Dividend

The company also recently declared a quarterly dividend, which will be paid on Tuesday, February 17th. Shareholders of record on Friday, January 16th will be issued a $1.73 dividend. This is a boost from AbbVie’s previous quarterly dividend of $1.64. The ex-dividend date of this dividend is Friday, January 16th. This represents a $6.92 dividend on an annualized basis and a yield of 3.2%. AbbVie’s payout ratio is 524.24%.

Analyst Ratings Changes

ABBV has been the topic of a number of research analyst reports. Berenberg Bank raised shares of AbbVie from a “hold” rating to a “buy” rating and increased their price target for the stock from $170.00 to $270.00 in a report on Wednesday, September 17th. Bank of America increased their target price on AbbVie from $220.00 to $251.00 and gave the company a “neutral” rating in a research note on Friday, October 3rd. Weiss Ratings restated a “hold (c)” rating on shares of AbbVie in a research report on Wednesday, October 8th. JPMorgan Chase & Co. upped their price objective on AbbVie from $250.00 to $260.00 and gave the stock an “overweight” rating in a report on Monday, November 3rd. Finally, BMO Capital Markets increased their price objective on AbbVie from $215.00 to $240.00 and gave the company an “outperform” rating in a research report on Friday, September 12th. Two equities research analysts have rated the stock with a Strong Buy rating, fifteen have given a Buy rating and ten have given a Hold rating to the company. According to MarketBeat.com, AbbVie has an average rating of “Moderate Buy” and a consensus price target of $236.57.

About AbbVie

AbbVie Inc discovers, develops, manufactures, and sells pharmaceuticals worldwide. The company offers Humira, an injection for autoimmune and intestinal Behçet's diseases, and pyoderma gangrenosum; Skyrizi to treat moderate to severe plaque psoriasis, psoriatic disease, and Crohn's disease; Rinvoq to treat rheumatoid and psoriatic arthritis, ankylosing spondylitis, atopic dermatitis, axial spondyloarthropathy, ulcerative colitis, and Crohn's disease; Imbruvica for the treatment of adult patients with blood cancers; Epkinly to treat lymphoma; Elahere to treat cancer; and Venclexta/Venclyxto to treat blood cancers.